Abstract
The development of acute lung injury (ALI) is always accompanied by remarkably increased production of cytokines in plasma. However, the pathogenesis of this inflammatory response is unclear. In this study, the hypothesis whether Interleukin 33 (IL-33) is induced in the ALI patients and the possible mechanism was tested. The levels of IL-33 were found to be significantly induced in plasma of the ALI patients. Addition of IL-33, enhanced mRNA expression of NLRP-3, Caspase-3, BAX and p53 of peripheral mononuclear blood cells (PBMCs), but inhibited mRNA expression of Caspase-1 found in ALI patients. By stimulating the PBMCs with recombinant Human Interleukin (rhIL)-33, we demonstrated that the chemokines Interleukin 1β (IL-1β), Interleukin 6 (IL-6), Interleukin 18 (IL-18) and Tumor Necrosis Factor (TNF-α) were significantly increased with IL-33 administration in a dose dependent way. Concomitantly, the increase of phosphorylated p38 and enhancement of cell apoptosis were also found in the PBMCs. However, by blocking the IL-33 signaling with p38 inhibitor (SB 203580), the cytokine production and apoptosis were apparently blocked in PBMCs. The present study provided evidences for the IL-33 molecular mechanism in ALI patients. It promots cell apoptosis and cytokines production via the MAPK/p38 signaling in PBMCs.
Keywords: Acute lung injury (ALI), inflammation, IL-33, PBMCs, p38.
Current Signal Transduction Therapy
Title:Pro-inflammatory and Pro-apoptotic Role of IL-33 in the Human Acute Lung Injury (ALI) Development
Volume: 10 Issue: 1
Author(s): Guoquan Pan, Yafeng Liang, Xu Chen, Lu Lu, Linxia Wang, Min Wang, Xiaojiao Ye and Chunxue Yan
Affiliation:
Keywords: Acute lung injury (ALI), inflammation, IL-33, PBMCs, p38.
Abstract: The development of acute lung injury (ALI) is always accompanied by remarkably increased production of cytokines in plasma. However, the pathogenesis of this inflammatory response is unclear. In this study, the hypothesis whether Interleukin 33 (IL-33) is induced in the ALI patients and the possible mechanism was tested. The levels of IL-33 were found to be significantly induced in plasma of the ALI patients. Addition of IL-33, enhanced mRNA expression of NLRP-3, Caspase-3, BAX and p53 of peripheral mononuclear blood cells (PBMCs), but inhibited mRNA expression of Caspase-1 found in ALI patients. By stimulating the PBMCs with recombinant Human Interleukin (rhIL)-33, we demonstrated that the chemokines Interleukin 1β (IL-1β), Interleukin 6 (IL-6), Interleukin 18 (IL-18) and Tumor Necrosis Factor (TNF-α) were significantly increased with IL-33 administration in a dose dependent way. Concomitantly, the increase of phosphorylated p38 and enhancement of cell apoptosis were also found in the PBMCs. However, by blocking the IL-33 signaling with p38 inhibitor (SB 203580), the cytokine production and apoptosis were apparently blocked in PBMCs. The present study provided evidences for the IL-33 molecular mechanism in ALI patients. It promots cell apoptosis and cytokines production via the MAPK/p38 signaling in PBMCs.
Export Options
About this article
Cite this article as:
Pan Guoquan, Liang Yafeng, Chen Xu, Lu Lu, Wang Linxia, Wang Min, Ye Xiaojiao and Yan Chunxue, Pro-inflammatory and Pro-apoptotic Role of IL-33 in the Human Acute Lung Injury (ALI) Development, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150407232651
DOI https://dx.doi.org/10.2174/1574362410666150407232651 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway
Current Alzheimer Research Complications of the Type 2 Diabetes Mellitus
Current Cardiology Reviews Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Therapeutic Proteins: A to Z
Protein & Peptide Letters Asymmetric Organocatalyzed Warfarin Synthesis in Aqueous and Nonaqueous Media: A Discussion in the Era of COVID-19 Pandemic
Current Organocatalysis Biologically Active Dietary Peptides
Mini-Reviews in Medicinal Chemistry Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Editorial (Thematic Issue: Nanopharmaceutics for Patient Care)
Current Nanomedicine Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Pathophysiology and Treatment of Diabetic Peripheral Neuropathy: The Case for Diabetic Neurovascular Function as an Essential Component
Current Diabetes Reviews Development of Peptide and Protein Based Radiopharmaceuticals
Current Pharmaceutical Design A Retrospective Study on <i>Gloriosa superba</i> and Its Main Active Constituents
The Natural Products Journal Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Aromatherapy and the Central Nerve System (CNS): Therapeutic Mechanism and its Associated Genes
Current Drug Targets